University of Sydney

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Sydney sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 2 completed later-stage tilt top decile by trial count

University of Sydney: 9 sponsored US clinical trials, 2 recruiting.

University of Sydney sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 4 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostatic Neoplasms, with 2 trials.

Top-decile sponsor footprint

University of Sydney ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING NA

Comparative Effectiveness OF Exercise, Cognitive Behavioural Therapy, AND Their Combination FOR People With Chronic Musculoskeletal Pain AND Poor Sleep: Sleepfit Trial

NCT07532070
RECRUITING Phase 3

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

NCT02582697
ACTIVE NOT RECRUITING Phase 3

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

NCT04136353
ACTIVE NOT RECRUITING Phase 2

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

NCT04195139
ACTIVE NOT RECRUITING Phase 3

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

NCT02446444
ACTIVE NOT RECRUITING Phase 3

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

NCT02446405
TERMINATED

Observational Study of Cardiovascular Disease.

NCT04128475
COMPLETED

Evaluation of a Patient-Reported Symptom Index for NMIBC

NCT03091764
COMPLETED NA

The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?

NCT02606058

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 4

Therapeutic Areas

Prostatic Neoplasms 2
Germ Cell Tumor 1
Preterm Birth 1
Glioblastoma Multiforme 1
Prostate Cancer 1

Where University of Sydney enrollment is open (later-stage tilt)

2 recruiting of 9 indexed (22% open); 2 completed (22%).

Phase mix: 4 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Prostatic Neoplasms (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Sydney: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

University of Sydney sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share University of Sydney4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
University of Sydney sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Sydney sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Sydney page

9 registered trials is a research-attention snapshot, not an endorsement of University of Sydney or any single study.

  • 2 of University of Sydney's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostatic Neoplasms is the condition University of Sydney studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostatic Neoplasms trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Sydney pipeline card: 9 registered trials from official public datasets.Report a data error.